Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Leukemia, Myeloid, Acute 17Leukemia, Myelomonocytic, Acute 11Leukemia, Monocytic, Acute 11Leukemia, Megakaryoblastic, Acute 11Leukemia, Erythroblastic, Acute 11Breast Neoplasms 11Congenital Abnormalities 9Leukemia 7Glioblastoma 7Recurrence 6Pancreatic Neoplasms 6Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Leukemia, Eosinophilic, Acute 5Leukemia, Basophilic, Acute 5Gliosarcoma 5Carcinoma, Non-Small-Cell Lung 5Anemia, Refractory, with Excess of Blasts 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Breast Neoplasms, Male 4Brain Neoplasms 4Blast Crisis 4Urinary Bladder Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3Thyroid Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Neuroblastoma 3Melanoma 3

Interventions

pembrolizumab 92Gemcitabine 56Nivolumab 50Cisplatin 39atezolizumab 37Carboplatin 30avelumab 29enfortumab vedotin 26Docetaxel 23Magnetic Resonance Spectroscopy 19Mitomycin 17Ipilimumab 17Paclitaxel 16Specimen Handling 14durvalumab 11toripalimab 10sacituzumab govitecan 10Pemetrexed 10cabozantinib 9Taxes 8vinflunine 7Cyclophosphamide 7tislelizumab 6Injections 6Bevacizumab 6pemigatinib 5fludarabine 5disitamab vedotin 5Standard of Care 5Radiosurgery 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Transitional Cell × tipifarnib × Clear all
NCT02535650 2022-03-08

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Samsung Medical Center

Phase 2 Unknown
19 enrolled
Genitourinary

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡